MT2018-19: COG ANBL1531 - A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- Age: Patient must be ≥ 365 days and ≤ 30 years of age at diagnosis - Diagnosis: Patients must have a diagnosis of neuroblastoma or ganglioneuroblastoma (nodular) verified by tumor pathology analysis or demonstration of clumps of tumor cells in bone marrow with elevated urinary catecholamine metabolites - The following disease groups are eligible: INRG Stage M & MYCN amplification or age > 547 days OR INRG Stage MS disease with MYCN amplification OR INRG Stage L2 disease with MYCN amplification

Exclusion Criteria:

- Patients who have an INRG Stage L2 tumor without amplification of MYCN - Patients with bone marrow failure syndromes - Pregnancy and Breastfeeding

Conditions & Interventions

Conditions:
Cancer
Keywords:
high risk, metastatic, neuroblastoma

More Information

Description: This partially randomized phase III trial studies iobenguane I-131 or ALK Inhibitor Therapy and standard therapy in treating younger patients (365 days to 30 years of age) with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma.
Study Contact: Allison Fullenkamp - fulle631@umn.edu
Principal Investigator: Robin Williams
Phase: PHASE3
IRB Number: SITE00000265